At a Glance
- Company: Novo Nordisk
- Location: Plainsboro, New Jersey, USA; Bagsværd, Denmark
- Headline figures: ~17% average weight loss if all patients stayed on treatment in OASIS 4; starting self‑pay price $149/month (~$5/day) for 1.5 mg
- Focus area: Obesity and cardiometabolic disease; once‑daily oral GLP‑1 (semaglutide 25 mg) for weight loss and CV risk reduction
- Next steps: Scale US access via >70,000 pharmacies and telehealth partners; expand use in adults with obesity or overweight and cardiovascular disease
What happened?
Novo Nordisk has launched the Wegovy pill, a once‑daily oral formulation of semaglutide, making the first and only GLP‑1 pill approved for weight loss in adults broadly available across the US. The pill, approved by the FDA in December 2025, is indicated alongside reduced‑calorie diet and increased physical activity for adults with obesity or overweight plus weight‑related medical problems, and also to reduce major cardiovascular event risk in adults with established cardiovascular disease.
Why does it matter?
The Wegovy pill brings injectable‑like GLP‑1 efficacy into an oral format, potentially appealing to people who were reluctant to use injections but need effective, long‑term obesity treatment. In the OASIS 4 phase 3 trial, once‑daily semaglutide 25 mg achieved about 14% average weight loss (13.6%) versus 2.4% with placebo, rising to ~17% (16.6%) versus 2.7% when assuming all patients remained on treatment, narrowing the gap to injectable Wegovy.
Who’s behind it?
Novo Nordisk is a global leader in diabetes and obesity medicines, now leveraging its semaglutide platform across both injectable and oral products for weight management and cardiovascular risk reduction. Millions of patients have already been treated with injectable Wegovy 2.4 mg since 2021, and the company is using that commercial footprint to support rapid uptake of the new oral option.
How was it achieved?
The FDA approval and US launch are based primarily on OASIS 4, a 64‑week, placebo‑controlled study in adults with obesity or overweight and comorbidities but without diabetes, where oral semaglutide 25 mg once daily produced significantly greater weight loss than placebo on top of lifestyle measures. Safety findings were consistent with injectable semaglutide, with gastrointestinal events such as nausea, diarrhoea and vomiting the most common adverse reactions, alongside class‑related warnings about potential thyroid tumours, pancreatitis, gallbladder disease, hypoglycaemia (with diabetes therapies), renal issues, and mood changes.
What’s next?
Wegovy pill is being rolled out through more than 70,000 US pharmacies, including CVS and Costco, plus telehealth partners such as Ro, LifeMD and WeightWatchers, as well as NovoCare Pharmacy and platforms like GoodRx, to expand access and reduce use of unapproved alternatives. Pricing is structured with multiple affordability programmes: self‑pay patients can start at $149 per month for the 1.5 mg starter dose (and 4 mg until mid‑April 2026), higher doses are set at up to $299 per month, and eligible commercially insured patients may pay as little as $25 per month with savings offers.
What are people saying?
Novo Nordisk executives describe Wegovy pill as a “significant innovation” that can bring GLP‑1‑based weight loss to people who have been “waiting on the sidelines” for a non‑injectable option, emphasising both efficacy (~17% weight loss if patients remain on therapy) and efforts to keep it accessible. Independent experts note that the pill offers a more convenient modality but stress that cost, insurance coverage and long‑term adherence will determine how far it can shift obesity care beyond existing injectable GLP‑1s.